Joint brief of the United States and the Federal Trade Commission urging reversal of district court order dismissing private antitrust action on grounds of the state action doctrine.
When a court considers a case whose outcome may affect consumers or competition, the FTC may file a “friend of the court” brief to provide information that can help the court make its decision in a way that protects consumers or promotes competition. To find a specific FTC brief, use the filters on this page.Displaying 61 - 80 of 100
In this amicus brief, filed at the invitation of the court, the FTC argues that, although the Fair Credit Reporting Act permits a business to obtain a consumer report if it provides the consumer with a firm offer of credit or insurance, the law is not satisfied if the business provides the consumer with an offer that is merely a sham. Accordingly, the brief contends that the district court erred in holding that plaintiff failed to state a claim upon which relief could be granted when her complaint alleged that the offer in the ad she received was a sham. The brief also argues that the court erred when it dismissed, without addressing, plaintiff's allegation that statutorily-mandated disclosures, which were made in tiny type, were not clear and conspicuous.
The Commission argues that the district court erred by dismissing Teva's complaint against Pfizer in this Hatch-Waxman Act case. Teva sought a declaratory judgment that its generic version of sertraline hydrochloride would not infringe a patent held by Pfizer (or that the patent was invalid). The brief argues that the court applied the wrong test to assess jurisdiction. It failed to take account of the fact that, unless Teva can obtain a court decision regarding Pfizer's patent, the FDA cannot give Teva approval to market its generic drug until 180 days after the first generic applicant (Ivax Pharmaceuticals) enters the market with its version. The brief also explains that the district court’s holding will leave subsequent generic applicants (such as Teva) powerless to prevent brand-name manufacturers and first generic applicants from greatly delaying other generic manufacturers from entering the market.
The Commission argued that the district court erred in holding that an insurance company cannot take “adverse action” against a consumer, as that term is defined in the Fair Credit Reporting Act, in connection with an initial offer of insurance. The brief disputes the district court’s holding, pursuant to which there would be no adverse action, even if, as a result information in a consumer report, the insurance company offered only a higher price or more onerous terms than it would have offered if the information in the report had been more favorable. The brief explains that the district court’s analysis is based on a misinterpretation of both the Act’s wording and its legislative history.
Joint brief of the United States and the Federal Trade Commission, as amici curiae, supporting petitioner Hoffmann-La Roche, and arguing that, under the Foreign Trade Antitrust Improvements Act, federal courts lack jurisdiction when a foreign plaintiff's claimed injury from an alleged antitrust conspiracy does not arise from the effects of that conspiracy on U.S. commerce. The brief also argues that prudential considerations support the conclusion that such actions are not properly brought in United States courts.
The Commission argued that the district court erred in holding that an insurance company does not take “adverse action” against a consumer, as that term is defined in the Fair Credit Reporting Act, when, based on information in a consumer report, the insurance company sets a price for insurance that is higher than the price it would have charged if the information had been more favorable. The brief explains that the district court misinterpreted both the wording of the Act and its legislative history when it held that there can be no “increase” in the price that an insurance company charges to a new customer regardless of the price that other customers are charged.
In this amicus brief, the FTC argues that a district court erred in holding that, because a private association of secondary schools had been deemed a state actor for constitutional purposes, it was protected by the antitrust state action doctrine. The brief explains that, in the antitrust context, “state action” narrowly refers only to actions undertaken in conformity with a policy clearly articulated by the sovereign state itself. The brief further explains that the alleged anticompetitive conduct here is not protected by the state action doctrine, because the state has not clearly articulated any such policy to displace competition.
Amicus brief, requested by the Court, addressing whether a private party has standing as a third party beneficiary to enforce a consent decree between the Federal Trade Commission and the defendant. The amicus brief explains that Supreme Court precedent, and subsequent cases interpreting it, have either foreclosed the possibility of third-party enforcement of government consent decrees or have at least limited third party enforcement to circumstances that are not present in this case. The brief also describes the Federal Trade Commission’s continuing efforts to address the matters pending between the Commission and the defendant.
Joint amicus brief of the United States and the Federal Trade Commission, urging the Georgia Supreme Court to reject a ruling by the Georgia State Bar Standing Committee on the Unlicensed Practice of Law, which had determined that real estate closings must be conducted by licensed attorneys. The brief points out that allowing non-lawyers to conduct closings is likely to lower prices and increase consumer choice, and that there is no indication that such lay closings will harm consumers in any way.
Amicus brief addressing proposed class action settlement, advising the court of the Commission's views on the difficulty of assessing the value of class relief based on coupons, and the need to evaluate the high level of attorney's fees requested here ($49 million) in light of the actual benefit to consumers and the likely strength of the consumers' claims.
Joint amicus brief of the United States and the Federal Trade Commission, urging the Court to deny the petition for certiorari. The brief explains that, although the court of appeals applied the wrong test in concluding that the Sherman Act did not apply to a global price-fixing conspiracy, the case is not appropriate for plenary review in light of the insufficient development of the record below and the absence of any conflict in the circuits on the questions presented.
Joint amicus brief of the United States and the Federal Trade Commission, urging reversal of the court of appeals' ruling, which had permitted a case to go forward under Section 2 of the Sherman Act, based on "essential facilities" and "monopoly leveraging" theories, despite the failure of plaintiff to allege exclusionary conduct under general Section 2 principles.
Joint brief of the United States and the Federal Trade Commission, as amici curiae, addressing the proper application of the Foreign Trade Antitrust Improvements Act where a foreign plaintiff's claimed injury from an alleged antitrust conspiracy does not arise from the effects of that conspiracy on U.S. commerce.
Memorandum of the Federal Trade Commission, as amicus curiae, addressing the propriety of de-listing a patent from FDA's "Orange Book," as a remedy for patent invalidity. The brief explains that improperly-maintained Orange Book listings may serve as a barrier to competition, and that there may be substantial consumer benefits to a de-listing remedy.
Amicus brief of the United States and the Federal Trade Commission, urging the grant of Supreme Court review in this case, to determine whether the court of appeals incorrectly invoked theories of "essential facilities" and "monopoly leveraging" to reverse dismissal of a claim against an alleged monopolist.
Memorandum of the Federal Trade Commission, as amicus curiae, submitted to the United States District Court for the Western District of Oklahoma, in a case challenging Oklahoma state restrictions on the sale of caskets. The memorandum does not take a position on the constitutionality of those restrictions, but explains why the policies of the Commission's Funeral Rule do not lend support to restrictions of this sort.
Amicus brief objecting to the proposed settlement’s claims process and the size of the proposed counsel fee in a case involving the allegedly deceptive marketing of credit repair services. The Commission argued that the claims process was unfair to certain class members and that the proposed legal fee for class counsel was excessive and would deplete the defendants’ resources and affect the FTC’s ability to obtain redress in its own broader case.
Amicus brief for the Federal Trade Commission, supporting argument of generic drug manufacturer that allegedly wrongful listing of patents in the FDA's "Orange Book" is not immune from antitrust liability.
Federal Trade Commission memorandum as amicus curiae (in the alternative to motion to intervene) to oppose grant of fees to private class action counsel, where much of the consumer recovery at issue resulted from the Commission's disgorgement action.
Amicus brief for the United States and the Federal Trade Commission, urging denial of Supreme Court review in a case raising an issue regarding the extent to which a foreign plaintiff can invoke the Sherman Act for damages flowing from a conspiracy that also has effects on U.S. commerce